Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Patients with hemophilia who have the same level of deficient factor(s) may express different
 severity of clinical presentation and bleeding tendency. Therefore a test which could
 determine overall hemostasis rather than simple concentration of a single deficient factor
 may correlate better with clinical phenotype in these patients.

 The investigators will therefore study the usefulness of global hemostatic methods
 (endogenous thrombin potential (ETP), overall hemostatic potential (OHP), fibrin clot
 structure) and microparticles in the prediction of severity of bleeding and estimation of
 response to the treatment in patients with hemophilia.

 Since hemophilia patients on prophylactic treatment virtually do not bleed, additional
 patients who are treated on demand only will be included enabling to study possible
 modulatory effects of different hemostatic factors (particularly prothrombotic and thrombin
 activatable fibrinolysis inhibitor (TAFI)) on clinical presentation. The investigators will
 correlate both those factors and clinical severity with global hemostatic methods.

 The investigators expect to prove that individual tailoring of the treatment, which may
 enable lowering the prophylactic dose of factor concentrate without increasing the risk of
 bleeding, is justified in some hemophilia patients. This approach would reduce the amount of
 necessary factor concentrate in certain patients and decrease the cost (which represents
 extensive burden for health care systems) of treatment without potential risk for the
 patients.
Inclusion Criteria:

 -  patients with bleeding disorders

 Exclusion Criteria:

 -  none